skip to content
Primary navigation


DrugOpsumit® (macitentan) [Actelion Pharmaceuticals US, Inc.]

March 2014

Therapeutic area - Pulmonary arterial hypertension (PAH)

Approval criteria

Patient has a diagnosis of PAH.

Quantity limits

Quantity limit = 34

Background information

OPSUMIT® is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension to delay disease progression. Due to the potential for fetal harm, OPSUMIT® requires a restricted distribution program for females.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top